For example, FSLLRY-NH2 was proven to inhibit neuropathic pain in rats with spinal cord injury, and reduce dermatophyte-associated in atopic dermatitis mouse models; a PAR2 antibody, MEDI0618, is undergoing a Phase I clinical trial, with an aim for the treatment of chronic pain in the future [194,201,202,203]. The gene discussed is F2RL1; the disease is atopic eczema.